42 results about "Brain spinal cord" patented technology

A method for classifying tissue in a magnetic resonance image. and particularly for measuring a volume of pathological tissue such as white tissue hyperintensity (leukoaraiosis) in the brain based on the segmentation of the intensity histogram of fluid attenuated inversion recovery (FLAIR) images is described. A magnetic resonance image of the brain of a subject is acquired, and a pixel intensity histogram is constructed from the image. A statistically-based regression analysis is applied to the histogram to determine upper and lower threshold values, which define different types of brain tissue, particularly normal brain, cerebral spinal fluid (CSF), or lesion.

Cerebral edema is the final common pathway for all CNS tissue injuries. The CSF is the major player for cerebral edema and the resultant blood perfusion deficit. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition includes two washing solutions, a first solution comprising an emulsion of oil, water, at least one osmotic agent and at least one emulsifier; the second solution comprising a pre-emulsion comprising water, oil, at least one osmotic agent, and at least one emulsifier. The method provides for withdrawing a volume of cerebrospinal fluid from the subarachnoid space and flushing the subarachnoid space with one or both washing solutions. Other materials may be added to the solutions to treat or prevent injury to nerve tissue resulting from injury or interruption of circulation.

The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA. Genetic instability is detected by observing an amplification or deletion of the small, tandem repeat DNA sequences in the microsatellite DNA which is at or corresponds to an allele. The invention is also a kit for practicing these methods.

Provided are conformable devices to measure subdermal fluid flow and related methods. A soft, stretchable and flexible substrate supports a thermal actuator and various specially positioned temperature sensors. A microprocessor in electronic communication with sensors calculates subdermal fluid flow from the measured upstream and downstream temperatures, as well as various application-dependent parameters. Devices and methods provided herein are particularly useful for measuring cerebral spinal fluid in a ventricular shunt placed for treatment of hydrocephalus.

The invention provides a feedback type intelligent injector, which includes a needle head and a needle seat. The needle head is provided with a first electrode and a second electrode for detecting the impedance of human tissue, and the first electrode and the second electrode are electrically connected with a main control device. The device is electrically connected with the display or reminding device. By adopting the above structure, the impedance of tissues and organs such as skin, muscle, effusion, and blood can be accurately measured, providing a basis for intelligent injection and extraction settings. During the injection process, avoid misplacement, embolism and other injuries, and accurately administer the drug; or perform precise monitoring during the liposuction process to avoid damage caused by wrong pumping; or conduct accurate scans during the extraction of tumor effusion and cerebrospinal fluid Prediction and precise positioning reduce medical risks and greatly improve doctor treatment efficiency.

Peptides that are bioactive regions and optimized bioactive regions of the human and mammalian Reg gene proteins and that are capable of generation of tissues such as brain, spinal cord, heart, liver, and kidney are described. In particular, 7-15-amino acid Reg peptides and optimized Reg peptides are disclosed which are capable of in vivo and ex vivo transformation of progenitor cells, progenitor tissue and stem cells into specialized cells and tissues, including functioning brain and spinal cord neurons, cardiac myocytes, liver hepatocytes and renal nephrons. Methods of in vivo and ex vivo transformation of progenitor cells into differentiated cells and tissues are also described.

The invention relates to a chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR comprises an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system. The invention relates to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid molecule comprising a sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. In one embodiment, the autoantigen encoded by the nucleic acid sequence comprises or consists of an N- methyl-D-aspartate receptor (NMDAR), or one or more NMDAR fragments. The invention further relates to the chimeric autoantibody receptor (CAAR) protein of the invention, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR) of the invention, a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and the use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

Systems and methods related to imaging biomarkers for determining neurological disease states of a subject are provided. In one embodiment, a method for producing an image indicative of a neurological disease using a magnetic resonance imaging (“MRI”) system is provided. The method includes directing the MRI system to perform a double inversion-recovery (“DIR”) pulse sequence to generate data where signals from gray matter and cerebral spinal fluid are substantially suppressed. The method also includes analyzing the DIR images, reconstructed from the acquired data, to identify cortical and white matter lesions. This includes identifying imaging biomarkers based on visual signatures of brain tissue, including white matter tissue. In some aspects, diffusion-weighted data may also be obtained using the MRI system. Diffusion-weighted data may be used in a tractography process to determine connectivities, or connectivity patterns between the identified lesions, including cortical lesions, to determine neurological disease states of the subject.

The invention relates to a treatment liquid composition, a treatment liquid kit and a method for transparentizing biological organs and performing immunolabeling simultaneously. The treatment liquid composition of the present invention comprises a clearing treatment liquid and a fluorescently labeled antibody at a volume ratio of 1:10 to 1:500 to the clearing treatment liquid, wherein the clearing treatment liquid comprises: carbohydrates, urea and non-ionic Surfactant. The present invention allows biomacromolecules such as antibodies to enter organs (brain, spinal cord, articular cartilage, (tumor-bearing) organs, etc.) while transparentizing them, so as to realize direct or indirect immune labeling on the scale of whole organs.

Electrical stimulation of specific facial and lingual nerves creates a more sustained pulsatility activity compared to stimulation of other cranial nerves. Pulsatility of arteries has intrinsic time constraints related to the time for vasodilation / constriction and time to return to baseline (TBL) after electrical stimulation which may affect the pulsatility response. Control of temporal patterning and the stimulation waveform maximizes the physiological response to cerebral pulsatility and its resulting effects on cerebral spinal fluid penetration into the brain parenchyma for a multitude of therapeutic uses including clearing misfolded proteins and / or administered pharmacological agents, diluting endogenous neurochemical concentrations within the brain, and reducing non-synaptic coupling.

The present invention provides an energy emission device comprising: one or a plurality of energy emitters for emitting at least one type of energy selected from the group consisting of an electromagnetic wave or an electromagnetic stimulation, an elastic wave, an oscillatory wave and heat to at least one position of a subject selected from the group consisting of the brain, the spinal cord, the cerebrospinal fluid or the flow passage thereof and the brain cell interstitial fluid or the flow passage thereof; an energy controller for controlling an amount of energy emitted from the energy emitters; and a sensor for obtaining information relating to wakefulness and / or a sleeping state of the subject, in which the energy controller controls the amount of energy emitted depending on the information relating to the wakefulness and / or the sleeping state.

The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification). The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and / or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain.

The present invention relates to efflux inhibitor compounds, compositions, and methods of using the same. More specifically, the instant invention comprises deuterated analogs of elacridar with superior pharmacokinetic properties such that it is now possible to facilitate accumulation and distribution of therapeutic agents to effective levels in cells or compartments protected by efflux transporter proteins such as Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-GP). Such transporter protected compartments include brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeballs, retina, inner ear, placenta, mammary gland, liver, biliary tract, kidney, intestines, lung, adrenal cortex, endometrium, hematopoietic cells, stem cells, and solid tumors. In other embodiments, the present invention comprises methods of using the instant deuterated analogs.

The present invention relates to a catheter device for a cranial cavity. Advantages of a conventional catheter structure for transferring a drug and a bodily liquid through different pathways are maintained, and the outer diameter of a catheter is regularly formed, so a brain positioning device which is useful in accurately positioning a catheter end in a brain ventricle can be easily used. A catheter rear side can be easily tunneled in a round space between a skull and skin, so an operation can be conveniently and easily performed and operation safety is remarkably improved. According to the present invention, the outer diameter of a catheter does not have a protruding part, so a catheter end can be accurately and easily disposed in a brain ventricle of an affected area by using a brain poisoning device. Also, a catheter can be easily induced to be bent through a round space between the top of a skull and skin, and a catheter rear end part can be easily discharged to the outside of a cranial cavity through a punching unit.

A conjugate series of CB and specific immunoglobulin IgG includes CB-A. beta resistant IgG, CB-antiviral IgG, CB-MnA, CB-IL-1 receptor resistant IgG and CB-Nogo resistant IgG, which can be used to respectively treat senile dementia, motor neuron disease, viral disease and cerebrospinal injury (apoplexy, cerebral infarction, paraplegia and hemiplegia).